Caricamento...
An Efficient Development Paradigm for Biosimilars
The current development paradigm for biosimilars required by regulators in highly regulated jurisdictions is derived from the development of novel drugs and is unnecessarily burdensome and inefficient. It requires the accumulation of data from analytical, nonclinical (including in vivo studies in so...
Salvato in:
| Pubblicato in: | BioDrugs |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Springer International Publishing
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6875142/ https://ncbi.nlm.nih.gov/pubmed/31388969 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40259-019-00371-4 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|